Atezolizumab Monotherapy versus Chemotherapy in Untreated Locally Advanced or Metastatic Urothelial Carcinoma (IMvigor130): Final Overall Survival Analysis from a Randomised, Controlled, Phase 3 Study – Beyond the Abstract
bladder cancer, Atezolizumab monotherapy versus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma, Atezolizumab, IMvigor130 trial, metastatic urothelial carcinoma (mUC), PD-L1 expression, CheckMate 901 trial, EV-302 trial, KEYNOTE-A39 trial.